NCT01905462 - Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK | Biotech Hunter

Enrollment

1,046

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Infections, Papillomavirus

Interventions

OTHER

Data Collection

Analyses of data collected within the CPRD GOLD database.

BIOLOGICAL

Cervarix

Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.

Trial Locations (1)

SW1W 9SZ

GSK Investigational Site, London